Quantification of Infant Motor Development to Predict Risk for Neurodevelopmental Disorders

项目总结/摘要 在这个K23职业发展奖，Rujuta Wilson博士将开发运动定量分析的培训， 发展，以帮助早期识别神经发育障碍（NDD）。威尔逊博士的长期研究 目标是成为运动发育领域的领先临床科学家，利用新颖的定量方法， 分析，以确定各种运动障碍的机制，生物标志物和治疗 受这些缺陷影响的发育人群。通过支持K23和浓缩的 在加州大学洛杉矶分校的跨学科培训环境和资源，威尔逊博士的目标是实现以下目标 培训目标：（1）发展理论模型和评估婴儿运动和发育的专业知识 轨迹，（2）获得最佳统计方法的知识和纵向建模，信号 处理和机器学习技术来分析复杂的定量运动数据， 预测模型，（3）熟练掌握临床研究设计的先进方法， 实施，以及（4）将K23培训和研究结果转化为R 01，利用运动风险标记来帮助 临床分层和监测有针对性的运动干预的发育结果。实现这些 威尔逊博士组建了一个模范导师团队，包括她的主要导师詹姆斯博士。 麦克拉肯是一位儿童精神病学家，数十年来一直致力于研究儿童和青少年的发展。 NDD临床试验的设计和实施;共同导师，Grace Baranek博士，感觉神经功能障碍研究的领导者， NDD的运动和行为风险标志物在生命的第一年;共同导师，大卫Elashoff博士，一个领导者， 生物统计学与高维数据集和传感器监测数据的广泛知识;合作者 和贡献者，威廉凯泽博士，贝丝史密斯，沙法利杰斯特，和苏珊布克海默，专家在先进的 信号处理和机器学习的分析技术，可穿戴传感器，高危婴儿研究，以及 神经影像学方法，分别在高危婴儿。运动障碍发生在一系列NDD中， 在病程早期出现，但由于缺乏 定量测量可以客观地识别这些早期运动障碍。的首要目标 所提出的纵向研究是（1）利用经验证的可穿戴传感器来获得 运动功能和识别NDD高风险婴儿的运动损伤（例如，有哥哥姐姐的婴儿 自闭症谱系障碍[ASD]）早在3个月大，（2）检查这些之间的关系 运动障碍的ASD症状和延迟的社会沟通，语言和认知。这 该提案将促进新的transdiagnosis运动表型分析工具的开发， 通知临床筛查，临床风险分层，以及一系列神经系统的干预研究 紊乱这些目标直接涉及NICHD研究的优先事项;特别是，“研究建立 智力和发育障碍症状的生物标志物和结果测量的有效性。

Project Summary/Abstract In this K23 career development award, Dr. Rujuta Wilson will develop training in quantitative analysis of motor development to aid in early identification of neurodevelopmental disorders (NDDs). Dr. Wilson’s longer-term goal is to be a leading clinician-scientist in motor development, utilizing novel quantitative methods and analyses to identify mechanisms, biomarkers, and treatments of motor impairments across diverse developmental populations affected by these impairments. Through the support of this K23 and the enriched transdisciplinary training environment and resources at UCLA, Dr. Wilson aims to accomplish the following training goals: (1) develop expertise in theoretical models and assessment of infant motor and developmental trajectories, (2) acquire knowledge of optimal statistical methods and skills in longitudinal modeling, signal processing, and machine learning techniques to analyze complex quantitative motor data and develop prediction models, (3) develop proficiency in advanced methods of clinical research design and implementation, and (4) translate the K23 training and findings into an R01 utilizing motor risk markers to aid in clinical stratification and monitor developmental outcomes of a targeted motor intervention. To achieve these goals, Dr. Wilson has assembled an exemplary mentorship team, including her primary mentor, Dr. James McCracken, a child psychiatrist with decades of research dedicated to studying development in children and in design and conduct of clinical trials in NDDs; co-mentor, Dr. Grace Baranek, a leader in the study of sensory- motor and behavioral risk markers of NDDs in the first year of life; co-mentor, Dr. David Elashoff, a leader of biostatistics with extensive knowledge of high dimensional data sets and sensor monitoring data; collaborators and contributors, Drs. William Kaiser, Beth Smith, Shafali Jeste, and Susan Bookheimer, experts in advanced analytic techniques of signal processing and machine learning, wearable sensors, high risk infant studies, and neuroimaging methods in high risk infants, respectively. Motor impairments occur across an array of NDDs and emerge early in disease course, but early identification remains an ongoing challenge due to lack of quantitative measures that can objectively identify these early motor impairments. The overarching goal of the proposed longitudinal study is to (1) utilize a validated wearable sensor to derive quantitative measurements of motor function and identify motor impairments in infants at high risk for NDDs (e.g., infants with an older sibling with Autism Spectrum Disorder [ASD]) as early as 3 months of age, and (2) examine the relationship of these motor impairments to symptoms of ASD and to delays in social communication, language, and cognition. This proposal will facilitate the development of novel transdiagnostic motor phenotyping tools that can be utilized to inform clinical screening, clinical risk stratification, and intervention studies across a range of neurologic disorders. These aims directly address NICHD research priorities; in particular, “research establishing the validity of biomarkers and outcome measures for intellectual and developmental disability symptoms.”